Celon Pharma Sa · GPW:CLN
Celon Pharma Sa — Q3 2024 Earnings Presentation
14 slides from Celon Pharma Sa's earnings presentation, Nov 21, 2024
Slide 1: Investor Presentation
INVESTOR PRESENTATION WARSAW // 21.11.2024
Slide 2: Disclaimer
Neither this presentation (the “Presentation”, references to which shall be deemed to include any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further enquiries) nor any copy of it nor the information contained herein is being is
Slide 3: Pharma Financials
PHARMA FINANCIALS
Slide 4: Generics
Generics Q1-2024 Q2-2024 Q3-2024 Q3-2023 9M-2024 9M-2023 Change Change All amounts in kPLN Actual Actual Actual Actual Actual Actual Q3'24 / Q3'23 9M'24 / 9M'23 Revenues 36 318 53 572 52 007 43 016 141 896 125 545 21% 13% Revenues from sales of 34 798 53 582 50 747 42 500 139 126 123 734 19% 12% med
Slide 5: R&D
R&D Q1-2024 Q2-2024 Q3-2024 Q3-2023 9M-2024 9M-2023 Change Change Q3'24 / All amounts in kPLN Actual Actual Actual Actual Actual Actual 9M'24 / 9M'23 Q3'23 Revenues 4 016 12 041 67 999 5 823 84 055 36 137 1068% 133% Revenues from sales of medicines - - - - - 0% 0% Other revenues - - 67 696 67 696 -
Slide 6: All segments
All segments Q1-2024 Q2-2024 Q3-2024 Q3-2023 9M-2024 9M-2023 Change Change All amounts in kPLN Actual Actual Actual Actual Actual Actual Q3'24 / Q3'23 9M'24 / 9M'23 Revenues 40 334 65 613 120 004 48 839 225 951 161 682 146% 40% Revenues from sales of 34 798 53 582 50 746 42 500 139 126 123 734 19% 1
Slide 7: Balance sheet
Balance sheet. A. The decrease in fixed assets as of September 30, 2024, compared to December 31, 2023, is related to the intensive capital expenditures incurred by the Company in previous years. The current CAPEX expenditures are mainly focused on maintaining existing fixed assets. B. Equity stakes
Slide 8: Branded Generics
PHARMA BRANDED GENERICS
Slide 9: Company's generic portfolio – strong market position of key products
Company's generic portfolio – strong market position of key products at Q32024 Salmex Zarixa Ketrel Valzek Donepex 20 000 18 000 16 000 Sales (PLN, 000) 14 000 12 000 10 000 8 000 6 000 4 000 2 000 0 11/23 12/23 01/24 02/24 03/24 04/24 05/24 06/24 07/24 08/24 09/24 10/24 Salmex 6 969 6 778 7 058 6 6
Slide 10: Innovative Business
PHARMA ININIOW NENA BUSINESS
Slide 11: Clinical pipeline - Key Milestones & Partnering 2024/2025
Clinical pipeline - Key Milestones & Partnering 2024/2025 Molecular Program Phase 1 Phase 2 Milestone Partnering status Target Neuropsychiatry NMDAR Agonist Falkieri Esketamine Treatment-Resistant Depression Ready to start Phase 3 Tang Capital LPP/Novohale Schizophrenia Phase 2 data completed CPL’36
Slide 12: Early stage pipeline status
Early stage pipeline status Program Molecular target Research Preclinical Development Milestone BsAbs targeting CPL’976 PD-1/PD-L1 - resistant Tox results H2 2025 Solid tumors tumors BsAbs targeting CPL’976- MMAE PD-1/PD-L1 - resistant tumors Solid tumors Tox results H2 2025 mRNA mRNA Vaccine - Trop
Slide 13: TransformRNA – mRNA Therapeutics generation platform project
Projekt „Rozwój Innowacyjnych Rozwiązań Terapeutycznych z wykorzystaniem technologii RNA (TransformRNA – mRNA Therapeutics generation platform)” dofinansowany ze środków budżetu państwa od Agencji Badań Medycznych/The project “Development of Innovative Therapeutic Solutions using RNA technology (Tra
Slide 14: QA
QA